GlaxoSmithKline releases positive data on Shingrix efficacy

By

Sharecast News | 06 Dec, 2017

Updated : 10:54

09:15 18/11/24

  • 1,317.00
  • 1.23%16.00
  • Max: 1,320.00
  • Min: 1,311.50
  • Volume: 679,808
  • MM 200 : n/a

GlaxoSmithKline released new data from a Phase III clinical study on Wednesday, which it said supports the safety and efficacy of Shingrix in preventing shingles when given to adults 18 years and above shortly after undergoing autologous haematopoietic stem cell transplant.

Last news